To the Editor:

I read with great interest the recent article by Bonito et al. \[[@B1]\] in a recent issue of your esteemed journal. The article is highly thought provoking. Geminin is rapidly emerging as a significant marker and prognostic indicator in a number of systemic malignancies besides breast malignancies.

A worse clinical outcome and correspondingly a lower relapse-free survival rate are seen in salivary gland carcinomas that express higher levels of geminin. The labeling index for salivary duct carcinomas is about 15.2% and associated with worse prognosis in comparison to acinic cell carcinomas which have a labeling index of 1.6% \[[@B2]\]. The mean labeling index for oral squamous cell carcinomas is 21.3% in comparison to 9.2% in oral dysplasia, thus making geminin a useful biomarker for malignant oral tumors \[[@B3]\]. A worse prognosis is seen in stage I-IV \"intestinal type\" gastric carcinomas which exhibit a higher geminin labeling index in comparison to those with lower geminin labeling indices \[[@B4]\]. A worse clinical prognosis is also seen in colorectal carcinomas which exhibit higher MCM7 and Ki-67 labeling indices in co-junction with a higher geminin labeling index \[[@B5]\].

Accentuated expression of geminin is seen in mammary tumors \[[@B6]\]. Not surprisingly, higher levels are associated with a poor clinical outcome in these tumors \[[@B7]\]. Geminin expression is altered in cervical carcinomas also and significantly affects cancer prognosis in addition to other markers such as CDC6 \[[@B8]\]. Interestingly, high grade astrocytomas with lower germinin labeling indices are associated with a worse prognosis in comparison to astrocytomas with a higher labeling index \[[@B9]\].

Clearly, geminin has a major role to play in systemic carcinogenesis and can serve as a significant marker of malignancy and disease prognosis in systemic tumors.
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